Dipyridamole
 Dipyridamole Injection

drug-information.ru

|Dipyridamole Dipyridamole Injection

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Dipyridamole

Dosage Form: Tablets

Rev NOVEMBER 2005

11001008

Rx only

Description:

Dipyridamole is a platelet inhibitor chemically described as 2,2",2"",2"""-[(4,8-Dipiperidinopyrimido [5,4-d] pyrimidine -2,6 - diyl) dinitrilo] tetraethanol. It has the following structural formula:

C24H40N8O4 Molecular Weight: 504.63

Dipyridamole is an odorless yellow crystalline powder, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and practically insoluble in water.

Dipyridamole Tablets, USP for oral administration contain:

Active Ingredient: 25 mg, 50 mg, and 75 mg; Dipyridamole USP 25 mg, 50 mg and 75 mg, respectively.

Inactive Ingredients: Colloidal silicon dioxide, hypromellose, lactose anhydrous, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, propylene glycol, stearic acid, sodium starch glycolate, and titanium dioxide.

Clinical Pharmacology:

It is believed that platelet reactivity and interaction with prosthetic cardiac valve surfaces, resulting in abnormally shortened platelet survival time, is a significant factor in thromboembolic complications occurring in connection with prosthetic heart valve replacement.

Dipyridamole tablets have been found to lengthen abnormally shortened platelet survival time in a dose-dependent manner.

In three randomized controlled clinical trials involving 854 patients who had undergone surgical placement of a prosthetic heart valve, Dipyridamole tablets, in combination with warfarin, decreased the incidence of postoperative thromboembolic events by 62 to 91% compared to warfarin treatment alone. The incidence of thromboembolic events in patients receiving the combination of Dipyridamole tablets and warfarin ranged from 1.2 to 1.8%. In three additional studies involving 392 patients taking Dipyridamole tablets and coumarin-like anticoagulants, the incidence of thromboembolic events ranged from 2.3 to 6.9%.

In these trials, the coumarin anticoagulant was begun between 24 hours and 4 days postoperatively, and the Dipyridamole tablets were begun between 24 hours and 10 days postoperatively. The length of follow-up in these trials varied from 1 to 2 years.

Dipyridamole tablets do not influence prothrombin time or activity measurements when administered with warfarin.

Mechanism of Action:

Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5 to1.9 mcg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A2-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3",5"-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP).

Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of Dipyridamole inhibit cyclic-3",5"-guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide).

Hemodynamics:

In dogs intraduodenal doses of Dipyridamole of 0.5 to 4 mg/kg produced dose-related decreases in systemic and coronary vascular resistance leading to decreases in systemic blood pressure and increases in coronary blood flow. Onset of action was in about 24 minutes and effects persisted for about 3 hours.

Similar effects were observed following IV Dipyridamole in doses ranging from 0.025 to 2 mg/kg.

In man the same qualitative hemodynamic effects have been observed. However, acute intravenous administration of Dipyridamole may worsen regional myocardial perfusion distal to partial occlusion of coronary arteries.

Pharmacokinetics and Metabolism:

Following an oral dose of Dipyridamole tablets, the average time to peak concentration is about 75 minutes. The decline in plasma concentration following a dose of Dipyridamole tablets fits a two-compartment model. The alpha half-life (the initial decline following peak concentration) is approximately 40 minutes. The beta half-life (the terminal decline in plasma concentration) is approximately 10 hours. Dipyridamole is highly bound to plasma proteins. It is metabolized in the liver where it is conjugated as a glucuronide and excreted with the bile.

Indications and Usage:

Dipyridamole Tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.

Contraindications:

Hypersensitivity to Dipyridamole and any of the other components.

Precautions:

General:

Coronary Artery Disease:

Dipyridamole has a vasodilatory effect and should be used with caution in patients with severe coronary artery disease (e.g., unstable angina or recently sustained myocardial infarction). Chest pain may be aggravated in patients with underlying coronary artery disease who are receiving Dipyridamole.

Hepatic Insufficiency:

Elevations of hepatic enzymes and hepatic failure have been reported in association with Dipyridamole administration.

Hypotension:

Dipyridamole should be used with caution in patients with hypotension since it can produce peripheral vasodilation.

Laboratory Tests:

Dipyridamole has been associated with elevated hepatic enzymes.

Drug Interactions:

No pharmacokinetic drug-drug interaction studies were conducted with Dipyridamole tablets. The following information was obtained from the literature.

Adenosine:

Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary.

Cholinesterase Inhibitors:

Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

In studies in which Dipyridamole was administered in the feed to mice (up to 111 weeks in males and females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of drug related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a mg/m2 basis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice and about twice the MRHD in rats. Mutagenicity tests of Dipyridamole with bacterial and mammalian cell systems were negative. There was no evidence of impaired fertility when Dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a mg/m2 basis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1250 mg/kg (more than 30 times the MRHD on a mg/m2 basis).

Pregnancy:

Teratogenic Effects:

Pregnancy Category B:

Reproduction studies have been performed in mice, rabbits and rats at oral Dipyridamole doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m2 basis) and have revealed no evidence of harm to the fetus due to Dipyridamole. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Dipyridamole should be used during pregnancy only if clearly needed.

Nursing Mothers:

As Dipyridamole is excreted in human milk, caution should be exercised when Dipyridamole tablets are administered to a nursing woman.

Pediatric Use:

Safety and effectiveness in the pediatric population below the age of 12 years has not been established.

Adverse Reactions:

Adverse reactions at therapeutic doses are usually minimal and transient. On long-term use of Dipyridamole tablets initial side effects usually disappear. The following reactions in Table 1 were reported in two heart valve replacement trials comparing Dipyridamole tablets and warfarin therapy to either warfarin alone or warfarin and placebo:

Table 1: Adverse Reactions Reported in 2 Heart Valve Replacement Trials
Adverse Reaction Dipyridamole Tablets/ Warfarin

Placebo/

Warfarin
Number of Patients 147 170
Dizziness 13.6% 8.2%
Abdominal distress 6.1% 3.5%
Headache 2.3% 0.0%
Rash 2.3% 1.1%

Other reactions from uncontrolled studies include diarrhea, vomiting, flushing and pruritus. In addition, angina pectoris has been reported rarely, and there have been rare reports of liver dysfunction. On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication.

When Dipyridamole tablets were administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone. In rare cases, increased bleeding during or after surgery has been observed.

In post-marketing reporting experience, there have been rare reports of hypersensitivity reactions (such as rash, urticaria, severe bronchospasm, and angioedema), larynx edema, fatigue, malaise, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis, thrombocytopenia, alopecia, cholelithiasis, hypotension, palpitation, and tachycardia.

OVERDOSAGE:

In case of real or suspected overdose, seek medical attention or contact a Poison Control Center immediately. Careful medical management is essential. Based upon the known hemodynamic effects of Dipyridamole, symptoms such as warm feeling, flushes, sweating, restlessness, feeling of weakness and dizziness may occur. A drop in blood pressure and tachycardia might also be observed.

Symptomatic treatment is recommended, possibly including a vasopressor drug. Gastric lavage should be considered. Administration of xanthine derivatives (e.g., aminophylline) may reverse the hemodynamic effects of Dipyridamole overdose. Since Dipyridamole is highly protein bound, dialysis is not likely to be of benefit.

Dosage and Administration:

Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement:

The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.

How Supplied:

Dipyridamole Tablets, USP are available as:

25 mg: White, round, film-coated, unscored tablets. Debossed with stylized b on one side and 252 on the other side. Available in bottles of:

90 Tablets NDC 0555-0252-14
100 Tablets NDC 0555-0252-02
500 Tablets NDC 0555-0252-04
1000 Tablets NDC 0555-0252-05
5000 Tablets NDC 0555-0252-06

50 mg: White, round, film-coated, unscored tablets. Debossed with stylized b on one side and 285 on the other side. Available in bottles of:

100 Tablets NDC 0555-0285-02
500 Tablets NDC 0555-0285-04
1000 Tablets NDC 0555-0285-05

75 mg: White, round, film-coated, unscored tablets. Debossed with BARR on one side and 286 on the other side. Available in bottles of:

100 Tablets NDC 0555-0286-02
500 Tablets NDC 0555-0286-04
1000 Tablets NDC 0555-0286-05

Dispense with a child-resistant closure in a tight, light-resistant container.

Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature].

MANUFACTURED BY
BARR LABORATORIES, INC.
POMONA, NY 10970

Rev NOVEMBER 2005 (v.4)
BR - 0252, 0285, 0286


Dipyridamole (Dipyridamole)
PRODUCT INFO
Product Code 0555-0252 Dosage Form TABLET, FILM COATED
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Dipyridamole (Dipyridamole) Active 25 MILLIGRAM  In 1 TABLET
colloidal silicon dioxide Inactive  
hypromellose Inactive  
lactose anhydrous Inactive  
magnesium stearate Inactive  
microcrystalline cellulose Inactive  
polyethylene glycol Inactive  
polysorbate 80 Inactive  
propylene glycol Inactive  
sodium starch glycolate Inactive  
stearic acid Inactive  
titanium dioxide Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE (WHITE) Score 1
Shape ROUND (ROUND) Symbol true
Imprint Code 252 Coating true
Size 6mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0555-0252-06 5000 TABLET In 1 BOTTLE None
2 0555-0252-05 1000 TABLET In 1 BOTTLE None
3 0555-0252-04 500 TABLET In 1 BOTTLE None
4 0555-0252-02 100 TABLET In 1 BOTTLE None
5 0555-0252-14 90 TABLET In 1 BOTTLE None

Dipyridamole (Dipyridamole)
PRODUCT INFO
Product Code 0555-0285 Dosage Form TABLET, FILM COATED
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Dipyridamole (Dipyridamole) Active 50 MILLIGRAM  In 1 TABLET
colloidal silicon dioxide Inactive  
hypromellose Inactive  
lactose anhydrous Inactive  
magnesium stearate Inactive  
microcrystalline cellulose Inactive  
polyethylene glycol Inactive  
polysorbate 80 Inactive  
propylene glycol Inactive  
sodium starch glycolate Inactive  
stearic acid Inactive  
titanium dioxide Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE (WHITE) Score 1
Shape ROUND (ROUND) Symbol true
Imprint Code 285 Coating true
Size 7mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0555-0285-02 100 TABLET In 1 BOTTLE None
2 0555-0285-04 500 TABLET In 1 BOTTLE None
3 0555-0285-05 1000 TABLET In 1 BOTTLE None

Dipyridamole (Dipyridamole)
PRODUCT INFO
Product Code 0555-0286 Dosage Form TABLET, FILM COATED
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Dipyridamole (Dipyridamole) Active 75 MILLIGRAM  In 1 TABLET
colloidal silicon dioxide Inactive  
hypromellose Inactive  
lactose anhydrous Inactive  
magnesium stearate Inactive  
microcrystalline cellulose Inactive  
polyethylene glycol Inactive  
polysorbate 80 Inactive  
propylene glycol Inactive  
sodium starch glycolate Inactive  
stearic acid Inactive  
titanium dioxide Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE (WHITE) Score 1
Shape ROUND (ROUND) Symbol true
Imprint Code BARR;286 Coating true
Size 9mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0555-0286-05 1000 TABLET In 1 BOTTLE None
2 0555-0286-04 500 TABLET In 1 BOTTLE None
3 0555-0286-02 100 TABLET In 1 BOTTLE None

Revised: 03/2007





Where can I get more information about Dipyridamole Dipyridamole Injection ? We recommend to use www.Drugs.com

Typical mistypes for Dipyridamole Dipyridamole Injection
sipyridamole dipyridamole injection, xipyridamole dipyridamole injection, cipyridamole dipyridamole injection, fipyridamole dipyridamole injection, ripyridamole dipyridamole injection, eipyridamole dipyridamole injection, dupyridamole dipyridamole injection, djpyridamole dipyridamole injection, dkpyridamole dipyridamole injection, dopyridamole dipyridamole injection, d9pyridamole dipyridamole injection, d8pyridamole dipyridamole injection, dioyridamole dipyridamole injection, dilyridamole dipyridamole injection, di-yridamole dipyridamole injection, di0yridamole dipyridamole injection, diptridamole dipyridamole injection, dipgridamole dipyridamole injection, diphridamole dipyridamole injection, dipuridamole dipyridamole injection, dip7ridamole dipyridamole injection, dip6ridamole dipyridamole injection, dipyeidamole dipyridamole injection, dipydidamole dipyridamole injection, dipyfidamole dipyridamole injection, dipytidamole dipyridamole injection, dipy5idamole dipyridamole injection, dipy4idamole dipyridamole injection, dipyrudamole dipyridamole injection, dipyrjdamole dipyridamole injection, dipyrkdamole dipyridamole injection, dipyrodamole dipyridamole injection, dipyr9damole dipyridamole injection, dipyr8damole dipyridamole injection, dipyrisamole dipyridamole injection, dipyrixamole dipyridamole injection, dipyricamole dipyridamole injection, dipyrifamole dipyridamole injection, dipyriramole dipyridamole injection, dipyrieamole dipyridamole injection, dipyridzmole dipyridamole injection, dipyridsmole dipyridamole injection, dipyridwmole dipyridamole injection, dipyridqmole dipyridamole injection, dipyridanole dipyridamole injection, dipyridakole dipyridamole injection, dipyridajole dipyridamole injection, dipyridamile dipyridamole injection, dipyridamkle dipyridamole injection, dipyridamlle dipyridamole injection, dipyridample dipyridamole injection, dipyridam0le dipyridamole injection, dipyridam9le dipyridamole injection, dipyridamoke dipyridamole injection, dipyridamope dipyridamole injection, dipyridamooe dipyridamole injection, dipyridamolw dipyridamole injection, dipyridamols dipyridamole injection, dipyridamold dipyridamole injection, dipyridamolr dipyridamole injection, dipyridamol4 dipyridamole injection, dipyridamol3 dipyridamole injection, dipyridamole sipyridamole injection, dipyridamole xipyridamole injection, dipyridamole cipyridamole injection, dipyridamole fipyridamole injection, dipyridamole ripyridamole injection, dipyridamole eipyridamole injection, dipyridamole dupyridamole injection, dipyridamole djpyridamole injection, dipyridamole dkpyridamole injection, dipyridamole dopyridamole injection, dipyridamole d9pyridamole injection, dipyridamole d8pyridamole injection, dipyridamole dioyridamole injection, dipyridamole dilyridamole injection, dipyridamole di-yridamole injection, dipyridamole di0yridamole injection, dipyridamole diptridamole injection, dipyridamole dipgridamole injection, dipyridamole diphridamole injection, dipyridamole dipuridamole injection, dipyridamole dip7ridamole injection, dipyridamole dip6ridamole injection, dipyridamole dipyeidamole injection, dipyridamole dipydidamole injection, dipyridamole dipyfidamole injection, dipyridamole dipytidamole injection, dipyridamole dipy5idamole injection, dipyridamole dipy4idamole injection, dipyridamole dipyrudamole injection, dipyridamole dipyrjdamole injection, dipyridamole dipyrkdamole injection, dipyridamole dipyrodamole injection, dipyridamole dipyr9damole injection, dipyridamole dipyr8damole injection, dipyridamole dipyrisamole injection, dipyridamole dipyrixamole injection, dipyridamole dipyricamole injection, dipyridamole dipyrifamole injection, dipyridamole dipyriramole injection, dipyridamole dipyrieamole injection, dipyridamole dipyridzmole injection, dipyridamole dipyridsmole injection, dipyridamole dipyridwmole injection, dipyridamole dipyridqmole injection, dipyridamole dipyridanole injection, dipyridamole dipyridakole injection, dipyridamole dipyridajole injection, dipyridamole dipyridamile injection, dipyridamole dipyridamkle injection, dipyridamole dipyridamlle injection, dipyridamole dipyridample injection, dipyridamole dipyridam0le injection, dipyridamole dipyridam9le injection, dipyridamole dipyridamoke injection, dipyridamole dipyridamope injection, dipyridamole dipyridamooe injection, dipyridamole dipyridamolw injection, dipyridamole dipyridamols injection, dipyridamole dipyridamold injection, dipyridamole dipyridamolr injection, dipyridamole dipyridamol4 injection, dipyridamole dipyridamol3 injection, dipyridamole dipyridamole unjection, dipyridamole dipyridamole jnjection, dipyridamole dipyridamole knjection, dipyridamole dipyridamole onjection, dipyridamole dipyridamole 9njection, dipyridamole dipyridamole 8njection, dipyridamole dipyridamole ibjection, dipyridamole dipyridamole imjection, dipyridamole dipyridamole ijjection, dipyridamole dipyridamole ihjection, dipyridamole dipyridamole inhection, dipyridamole dipyridamole innection, dipyridamole dipyridamole inmection, dipyridamole dipyridamole inkection, dipyridamole dipyridamole iniection, dipyridamole dipyridamole inuection, dipyridamole dipyridamole injwction, dipyridamole dipyridamole injsction, dipyridamole dipyridamole injdction, dipyridamole dipyridamole injrction, dipyridamole dipyridamole inj4ction, dipyridamole dipyridamole inj3ction, dipyridamole dipyridamole injextion, dipyridamole dipyridamole injevtion, dipyridamole dipyridamole injeftion, dipyridamole dipyridamole injedtion, dipyridamole dipyridamole injecrion, dipyridamole dipyridamole injecfion, dipyridamole dipyridamole injecgion, dipyridamole dipyridamole injecyion, dipyridamole dipyridamole injec6ion, dipyridamole dipyridamole injec5ion, dipyridamole dipyridamole injectuon, dipyridamole dipyridamole injectjon, dipyridamole dipyridamole injectkon, dipyridamole dipyridamole injectoon, dipyridamole dipyridamole inject9on, dipyridamole dipyridamole inject8on, dipyridamole dipyridamole injectiin, dipyridamole dipyridamole injectikn, dipyridamole dipyridamole injectiln, dipyridamole dipyridamole injectipn, dipyridamole dipyridamole injecti0n, dipyridamole dipyridamole injecti9n, dipyridamole dipyridamole injectiob, dipyridamole dipyridamole injectiom, dipyridamole dipyridamole injectioj, dipyridamole dipyridamole injectioh, ipyridamole dipyridamole injection, dpyridamole dipyridamole injection, diyridamole dipyridamole injection, dipridamole dipyridamole injection, dipyidamole dipyridamole injection, dipyrdamole dipyridamole injection, dipyriamole dipyridamole injection, dipyridmole dipyridamole injection, dipyridaole dipyridamole injection, dipyridamle dipyridamole injection, dipyridamoe dipyridamole injection, dipyridamol dipyridamole injection, dipyridamole dipyridamole injection, dipyridamole dipyridamole injection, dipyridamole ipyridamole injection, dipyridamole dpyridamole injection, dipyridamole diyridamole injection, dipyridamole dipridamole injection, dipyridamole dipyidamole injection, dipyridamole dipyrdamole injection, dipyridamole dipyriamole injection, dipyridamole dipyridmole injection, dipyridamole dipyridaole injection, dipyridamole dipyridamle injection, dipyridamole dipyridamoe injection, dipyridamole dipyridamol injection, dipyridamole dipyridamoleinjection, dipyridamole dipyridamole njection, dipyridamole dipyridamole ijection, dipyridamole dipyridamole inection, dipyridamole dipyridamole injction, dipyridamole dipyridamole injetion, dipyridamole dipyridamole injecion, dipyridamole dipyridamole injecton, dipyridamole dipyridamole injectin, dipyridamole dipyridamole injectio, idpyridamole dipyridamole injection, dpiyridamole dipyridamole injection, diypridamole dipyridamole injection, dipryidamole dipyridamole injection, dipyirdamole dipyridamole injection, dipyrdiamole dipyridamole injection, dipyriadmole dipyridamole injection, dipyridmaole dipyridamole injection, dipyridaomle dipyridamole injection, dipyridamloe dipyridamole injection, dipyridamoel dipyridamole injection, dipyridamol e dipyridamole injection, dipyridamole dipyridamole injection, dipyridamole d ipyridamole injection, dipyridamole idpyridamole injection, dipyridamole dpiyridamole injection, dipyridamole diypridamole injection, dipyridamole dipryidamole injection, dipyridamole dipyirdamole injection, dipyridamole dipyrdiamole injection, dipyridamole dipyriadmole injection, dipyridamole dipyridmaole injection, dipyridamole dipyridaomle injection, dipyridamole dipyridamloe injection, dipyridamole dipyridamoel injection, dipyridamole dipyridamol einjection, dipyridamole dipyridamolei njection, dipyridamole dipyridamole nijection, dipyridamole dipyridamole ijnection, dipyridamole dipyridamole inejction, dipyridamole dipyridamole injcetion, dipyridamole dipyridamole injetcion, dipyridamole dipyridamole injeciton, dipyridamole dipyridamole injectoin, dipyridamole dipyridamole injectino, ddipyridamole dipyridamole injection, diipyridamole dipyridamole injection, dippyridamole dipyridamole injection, dipyyridamole dipyridamole injection, dipyrridamole dipyridamole injection, dipyriidamole dipyridamole injection, dipyriddamole dipyridamole injection, dipyridaamole dipyridamole injection, dipyridammole dipyridamole injection, dipyridamoole dipyridamole injection, dipyridamolle dipyridamole injection, dipyridamolee dipyridamole injection, dipyridamole dipyridamole injection, dipyridamole dipyridamole injection, dipyridamole ddipyridamole injection, dipyridamole diipyridamole injection, dipyridamole dippyridamole injection, dipyridamole dipyyridamole injection, dipyridamole dipyrridamole injection, dipyridamole dipyriidamole injection, dipyridamole dipyriddamole injection, dipyridamole dipyridaamole injection, dipyridamole dipyridammole injection, dipyridamole dipyridamoole injection, dipyridamole dipyridamolle injection, dipyridamole dipyridamolee injection, dipyridamole dipyridamole injection, dipyridamole dipyridamole iinjection, dipyridamole dipyridamole innjection, dipyridamole dipyridamole injjection, dipyridamole dipyridamole injeection, dipyridamole dipyridamole injecction, dipyridamole dipyridamole injecttion, dipyridamole dipyridamole injectiion, dipyridamole dipyridamole injectioon, dipyridamole dipyridamole injectionn, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved